Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017 (2017), Article ID 4184879, 4 pages
https://doi.org/10.1155/2017/4184879
Case Report

Small Split Doses of CD34+ Peripheral Blood Stem Cells to Support Repeated Cycles of Nonmyeloablative Chemotherapy

1Division of Hematology/Oncology, Department of Pediatrics, Children’s Hospital of Michigan, Wayne State University, 3901 Beaubien Street, Detroit, MI 48201, USA
2Institute for Pediatric Oncology, N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye Shosse, Moscow 115478, Russia

Correspondence should be addressed to Maxim Yankelevich

Received 18 May 2017; Revised 6 August 2017; Accepted 25 October 2017; Published 12 November 2017

Academic Editor: Josep M. Ribera

Copyright © 2017 Maxim Yankelevich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Cairo, V. Shen, M. D. Krailo et al., “Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report,” Journal of Pediatric Hematology/Oncology, vol. 23, no. 1, pp. 30–38, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. C. H. Weaver, B. Hazelton, R. Birch et al., “An analysis of engraftment kinetics as a function of the CD34+ content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy,” Blood, vol. 86, no. 10, pp. 3961–3968, 1995. View at Google Scholar
  3. C. L. Shapiro, L. Ayash, L. J. Webb et al., “Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients,” Journal of Clinical Oncology, vol. 15, no. 2, pp. 674–683, 1997. View at Publisher · View at Google Scholar
  4. G. D. Long, R. S. Negrin, C. F. Hoyle et al., “Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies,” Cancer, vol. 76, no. 5, pp. 860–868, 1995. View at Publisher · View at Google Scholar
  5. R. Pettengell, P. J. Woll, N. Thatcher, T. M. Dexter, and N. G. Testa, “Multicycle, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood,” Journal of Clinical Oncology, vol. 13, no. 1, pp. 148–156, 1995. View at Publisher · View at Google Scholar
  6. D. S. Hawkins, J. Felgenhauer, J. Park et al., “Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas,” Cancer, vol. 95, no. 6, pp. 1354–1365, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. K. R. Pradhan, C. S. Johnson, T. A. Vik, L. S. Sender, and S. G. Kreissman, “A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support,” Pediatric Blood and Cancer, vol. 46, no. 7, pp. 793–802, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Bensimhon, J. G. Villablanca, L. S. Sender et al., “Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced neuroblastoma: a report from the Children’s Oncology Group,” Pediatric Blood and Cancer, vol. 54, no. 4, pp. 569–602, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. R. I. Jakacki, C. Jamison, S. A. Heifetz, K. Caldemeyer, M. Hanna, and L. Sender, “Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies,” Medical and Pediatric Oncology, vol. 29, no. 6, pp. 553–559, 1997. View at Publisher · View at Google Scholar
  10. S. Leyvraz, L. Perey, G. Rosti et al., “Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation,” Journal of Clinical Oncology, vol. 17, no. 11, pp. 3531–3539, 1999. View at Publisher · View at Google Scholar
  11. P. Lorigan, P. J. Woll, M. E. R. O’Brien, L. F. Ashcroft, M. R. Sampson, and N. Thatcher, “Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer,” Journal of the National Cancer Institute, vol. 97, no. 9, pp. 666–674, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Leyvraz, S. Pampallona, G. Martinelli et al., “A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial,” Journal of the National Cancer Institute, vol. 100, no. 8, pp. 533–541, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Van Winkle, A. Angiolillo, M. Krailo et al., “Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience,” Pediatric Blood and Cancer, vol. 44, no. 4, pp. 338–347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Yankelevich, I. Dolgopolov, R. Ravshanova et al., “Efficacy and toxicity of ICE/CCE chemotherapy with or without GM-CSF in relapsed or refractory Wilms’ tumor. A single institution study,” International Journal of Pediatric Hematology/Oncology, vol. 6, pp. 331–338, 2000. View at Google Scholar
  15. F. Bracho, M. D. Krailo, V. Shen et al., “A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities,” Clinical Cancer Research, vol. 7, no. 1, pp. 58–67, 2001. View at Google Scholar
  16. M. S. Cairo, V. Davenport, O. Bessmertny et al., “Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study,” British Journal of Haematology, vol. 128, no. 1, pp. 49–58, 2004. View at Publisher · View at Google Scholar · View at Scopus